MedTrace Logo

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

NCT00964730 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2010-04-07

No results posted yet for this study

Summary

The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo

Conditions

  • Healthy

Interventions

DRUG

Talampanel

titrated to 50mg three times a day over 9 days and a single dose administered on Day 10

DRUG

Moxifloxacin

Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10

DRUG

Placebo

administered three times a day over 9 days and a single dose administered on Day 10

Sponsors & Collaborators

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Craig R Sprenger, MD · Cetero Research - Fargo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-01-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964730 on ClinicalTrials.gov